Business Context and Reporting Period
Company: RXi Pharmaceuticals Corporation (Note: Metadata lists "Phio Pharmaceuticals Corp.", but the filing text identifies the registrant as RXi Pharmaceuticals Corporation).
Filing Type: Form 8-K (Current Report)
Date of Report: April 22, 2014
Event: Entry into a Material Definitive Agreement (Purchase Agreement) with Lincoln Park Capital Fund, LLC ("LPC").
Key Financial Metrics and Transaction Details
- Total Offering Capacity: Up to $20,000,000 in common stock.
- Initial Purchase: $2,000,000 at $4.00 per share.
- Contingent Purchase: Additional $1,000,000 at prevailing prices upon filing of an investigational new drug application (IND) for an ocular indication.
- Remaining Capacity: Up to $17,000,000 available over a 30-month term.
- Issuance Limits: Up to 50,000 shares per purchase date (not to exceed $500,000 proceeds per date).
- Pricing Mechanism: Based on prevailing market price, subject to a "Floor Price" defined in the agreement. No upper price limit.
- Upfront Consideration: 100,000 shares issued to LPC at $4.00/share ($400,000 value) with no cash proceeds to the company.
- Use of Proceeds: Working capital, funding development programs for an ocular indication, and general corporate purposes.
Material Changes and Operational Impact
The filing does not report changes to historical revenue, profit, or cash flow. The material change is the establishment of a new equity financing facility. The company retains sole discretion over the timing and amount of sales, allowing for flexible capital raising based on market conditions and operational needs.
Guidance, Outlook, and Risks
- Outlook: The company intends to utilize the facility to fund specific development programs for an ocular indication.
- Conditions: Future sales are subject to market conditions, trading price, and the company's determination of appropriate funding sources.
- Termination Rights: The company may terminate the Purchase Agreement at any time without cost or penalty.
- Risks: Actual sales depend on the company's discretion and market conditions; the agreement includes customary representations, warranties, and indemnification obligations.
Investor Verification Checklist
- Verify the exact terms of the "Floor Price" and "threshold price" for accelerated purchases in Exhibit 10.1 (Purchase Agreement).
- Confirm the status of the investigational new drug application (IND) for the ocular indication to assess the likelihood of the $1,000,000 contingent purchase.
- Review the effective shelf registration statement (Form S-3, No. 333-194956) for any additional restrictions on share issuance.
- Assess the dilution impact of the initial 100,000 shares issued as upfront consideration and potential future issuances up to $20 million.